Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by NightHawk1987on May 16, 2020 3:39pm
94 Views
Post# 31038321

RE:RE:Finding Ifenprodyl on super computer

RE:RE:Finding Ifenprodyl on super computerGreat, thank you. I figured there has to be similar drugs out there. But of course, they would be way behind in the race, so in the short term we would not be affected. But in a year from now we would. Since Ifenprodyl has been around since the 70's, it is no secret to the pharma industry. Once the cat is out of the bag is what slightly concerns me. Other company's will likely say hey, I've got a drug that will do the exact same thing, and if they are a big company with a lot of pull, I'm afraid they can bully their way in front of the line. That said, I am very pleased with the professionalism and steady progress algernon has made. They are doing it the right way, and not filling the media with BS or fake news. Yes, we investers might get frustrated with the lack of NR, but it is much better than saying we have the cure! Without even truly knowing, like some other companies are doing. Much respect for algernon.
<< Previous
Bullboard Posts
Next >>